CAMERON VANDENAKKER: Open Payments
NPI 1376328971 · HUNTINGTON BEACH, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,858 in 275 payments from 22 companies in 2025. Trend: 2023 $0 · 2024 $2,102 · 2025 $6,858
Food & beverage: $6,858
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 47 | $1,047 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 40 | $1,042 |
| Janssen Pharmaceuticals, Inc | 19 | $794 |
| Neurocrine BioSciences, Inc. | 22 | $731 |
| Teva Pharmaceuticals USA, Inc. | 37 | $712 |
| Alkermes, Inc. | 14 | $487 |
| Vanda Pharmaceuticals Inc. | 17 | $378 |
| Otsuka America Pharmaceutical, Inc. | 14 | $352 |
| Lundbeck LLC | 18 | $348 |
| Axsome Therapeutics, Inc. | 8 | $172 |
Products named: VRAYLAR, CAPLYTA, INGREZZA, SPRAVATO, REXULTI, AUSTEDO XR, FANAPT, ARISTADA.
Industry payments across CA — which companies pay providers there.
